Erysipelas (MONDO:0001266): A Comprehensive Disease Characterization

Summary

Erysipelas is an acute, sharply demarcated bacterial infection of the superficial dermis and dermal lymphatics, caused predominantly by β-hemolytic streptococci — chiefly Streptococcus pyogenes (group A streptococcus, GAS) and Lancefield groups C and G (S. dysgalactiae subsp. equisimilis, GCS/GGS). Bacteria enter through a breached cutaneous barrier — most often interdigital tinea pedis (toe-web intertrigo), traumatic wounds, or excoriated dermatoses — and in the setting of impaired lymphatic drainage (leg edema, lymphedema, obesity, venous insufficiency) proliferate to produce a fiery-red, raised, well-marginated plaque accompanied by the abrupt onset of fever and chills. Unlike most entries in a disease knowledge base, erysipelas is not a genetic disorder: it is an environmentally and microbiologically driven infection, a clinical diagnosis with no causal genes, pathogenic variants, or inheritance pattern.

The disease is leg-predominant (~90% of cases), affects adults and the elderly with a female predominance in most hospital series, shows seasonal (summer) clustering, and is strongly recurrence-prone. Its pathophysiology is dominated by a self-reinforcing erysipelas–lymphedema vicious cycle: pre-existing (often subclinical) lymphatic impairment predisposes to infection, and each infectious episode further damages lymphatics, worsening edema and increasing the risk of the next episode, culminating in some cases in elephantiasis nostras verrucosa. Management rests on narrow-spectrum penicillin, to which erysipelas responds rapidly (≈98% within 2 days), and guideline-adherent narrow-spectrum therapy is associated with better outcomes. Recurrence is countered by treating the portal of entry (antifungal therapy for tinea pedis), edema/lymphedema management, and — after repeated episodes — low-dose prophylactic penicillin V, whose efficacy during treatment is confirmed by two randomized controlled trials (PATCH I & II) and a Cochrane systematic review.

A crucial nosological point for knowledge-base curation: streptococcal erysipelas (the subject of this report, MONDO:0001266) is distinct from the identically named Erysipelothrix rhusiopathiae diseases — swine erysipelas (a veterinary disease of pigs) and human erysipeloid (Baker-Rosenbach disease, an occupational zoonosis). These share a name and, historically, clinical resemblance, but have a completely different etiologic agent, epidemiology, and reservoir.

Key Findings

Finding 1 — β-hemolytic streptococci are the predominant cause

Erysipelas is overwhelmingly a streptococcal infection. In a large retrospective cohort of 1,142 erysipelas episodes (981 patients), wound cultures grew group A streptococci (GAS, n=56), group G streptococci (GGS, n=53), group C streptococci (GCS, n=11), and Staphylococcus aureus (n=153); blood cultures (obtained in 49% of episodes) were positive in 50, most commonly GGS (n=21) followed by GAS (n=13) (PMID: 26424182). Because superficial cultures frequently recover skin-colonizing S. aureus that is not the true pathogen, serologic and prospective data are decisive. In a prospective cellulitis study (n=216), β-hemolytic streptococcal etiology was confirmed serologically or by culture in 72% (146/203) of cases, rising to 85% when probable cases were included; in lower-extremity infection, GCS/GGS were actually more common than GAS (36 vs 22) (PMID: 26734653).

"Wound cultures were taken in 343 episodes and 56 grew group A streptococci (GAS), 53 grew group G streptococci (GGS), 11 grew group C streptococci (GCS), and 153 grew Staphylococcus aureus." (PMID: 26424182)

"Serology or blood or tissue culture confirmed β-hemolytic streptococcal (BHS) etiology in 72% (146 of 203) of cases." (PMID: 26734653)

The relevant pathogens (NCBITaxon suggestions): Streptococcus pyogenes (NCBITaxon:1314), Streptococcus dysgalactiae subsp. equisimilis (NCBITaxon:119602). Group C/G streptococci carry virulence factors closely paralleling GAS — M protein, streptolysin O, streptolysin S, streptokinase, hyaluronidase, and C5a peptidase (PMID: 20607346).

Finding 2 — Skin barrier disruption and leg edema/lymphedema are the dominant risk factors

The two strongest, most reproducible risk factors are a breach in the skin barrier and leg edema. In a Tunisian multicenter case-control study (114 cases, 208 matched controls), multivariate analysis showed that disruption of the cutaneous barrier (traumatic wound, toe-web intertrigo, excoriated dermatosis, plantar squamous lesions) carried an odds ratio of 13.6 (95% CI 6.0–31) and leg edema an OR of 7.0 (95% CI 1.3–38); notably there was no association with diabetes, alcoholism, or smoking (PMID: 16484815). A large population-based case-control study of severe lower-leg cellulitis (29,062 case-control pairs) independently confirmed tinea pedis (AOR 3.05, 95% CI 1.45–6.42), varicose veins (AOR 2.95), lymphoedema (AOR 2.65), and obesity (AOR 2.05); incidence reached 204.8/100,000 by 2013, rising 4.7%/year (PMID: 29427797).

"disruption of the cutaneous barrier ... and leg edema were independently associated with erysipelas of the leg, with respective odds ratios of 13.6 (95% confidence interval: 6.0-31) and 7.0 (1.3-38)" (PMID: 16484815)

"varicose veins (AOR 2.95, 95% CI 2.50-3.48, p < 0.001), lymphoedema (AOR 2.65, 95% CI 1.71-4.10, p < 0.001), tinea pedis (AOR 3.05, 95% CI 1.45-6.42, p 0.003)" (PMID: 29427797)

The clinical corollary is that toe-web intertrigo is a high-attributable-risk, modifiable portal of entry, and secondary prevention targeting it has long been advocated (PMID: 11319357).

Finding 3 — Prophylactic low-dose penicillin V reduces recurrence

Recurrence prevention is evidence-based. In the PATCH I double-blind RCT (n=274, patients with ≥2 prior episodes), penicillin V 250 mg twice daily for 12 months reduced recurrence during prophylaxis to 22% (30/136) vs 37% (51/138) on placebo — HR 0.55 (95% CI 0.35–0.86, P=0.01), number-needed-to-treat ≈5 (PMID: 23635049). The protective effect waned after stopping the drug. PATCH II (n=123, mostly patients with a single prior episode) showed a concordant but non-significant 47% risk reduction (HR 0.53, 95% CI 0.26–1.07, P=0.08) (PMID: 21910701). A pooled economic analysis (n=397) found a 29% reduction in recurrences (IRR 0.71, 95% CI 0.53–0.90, P=0.02) and cost-effectiveness (PMID: 24551029).

"30 of 136 participants in the penicillin group (22%) had a recurrence, as compared with 51 of 138 participants in the placebo group (37%) (hazard ratio, 0.55; ... P=0.01)" (PMID: 23635049)

Finding 4 — Rapid penicillin response; narrow-spectrum guideline adherence improves outcomes

Erysipelas responds rapidly to penicillin: in a retrospective study, 98.3% of erysipelas patients responded within 2 days to Penicillin G, and constitutional symptoms (chills/fever) preceded or coincided with erythema in 91.4% of erysipelas vs only 36.2% of cellulitis patients — supporting clinical differentiation (PMID: 41562377). In prospective facial cellulitis (n=65), β-hemolytic streptococcal etiology was probable/confirmed in 75% and penicillin(-class) monotherapy cured 68% (PMID: 28768452). In a cohort of 630 erysipelas/cellulitis cases, adherence to narrow-spectrum guidelines was associated with fewer poor outcomes (6.3% vs 12.7%, p=0.007); bacteremia (AOR 5.21) and peripheral arterial disease (AOR 4.80) predicted poor outcome (PMID: 30685804).

"Of patients with erysipelas, 98.3% responded within 2 days to penicillin" (PMID: 41562377)

"A poor outcome was recorded in 54 (8.5%) patients, less frequently in case of adherence to guidelines: 26/410 (6.3%) vs 28/220 (12.7%), p = 0.007" (PMID: 30685804)

Finding 5 — Erysipelas and lymphedema form a self-reinforcing vicious cycle

Lymphatic dysfunction is both cause and consequence. Lymphoscintigraphy of 106 post-erysipelas patients found subclinical lymphedema in the clinically unaffected leg in 82%, rising from 74% after a single episode to 100% after ≥3 episodes — implicating pre-existing lymphatic impairment as a primary trigger and demonstrating cumulative damage (PMID: 40542699). A prospective cohort of 428 patients identified obesity, diabetes mellitus, venous insufficiency, lymphedema, and prior surgery as independent risk factors for recurrence (Cox model, all p<0.05) (PMID: 33413190). A retrospective-prospective cohort (n=313) found recurrent erysipelas significantly associated with obesity (p<0.0001), chronic edema/lymphedema, peripheral arterial disease, fungal foot infection, and tonsillectomy (p=0.000001) (PMID: 30976336).

"Subclinical lymphedema on the unaffected leg was found in 82% of patients" (PMID: 40542699)

Finding 6 — Epidemiology: adult/elderly, female-predominant, leg-predominant, seasonal

Hospital cohorts converge: 428 patients (mean age 58.6 y, 51% women; hypertension 51.6%, diabetes 41.6%, venous insufficiency 36.2%, obesity 12.1%, lymphedema 4.2%; seasonal) (PMID: 20147345); a Tunisian series of 647 patients (mean age 44.7 y, M:F ≈1.55, lower limbs 91.2%, portal of entry 76.7% mainly toe-web intertrigo, prior erysipelas 26.1%, good outcome 87.8% on IM penicillin G ×10 days) (PMID: 15822466); and a 10-year study (n=319, median age 63 y, 65% female, summer-predominant, lower limb 59.2%, recurrence 67.3%, complications 25% including abscess, lymphangitis, and elephantiasis) (PMID: 18069381).

"Erysipelas predominately involved in the lower limbs (91.2%). Antecedents of erysipelas were found in 26.12 %. Portal of entry was found in 76.66% represented essentially by toe-web intertrigo." (PMID: 15822466)

"Complications, such as abscess formation, lymphangitis, venous insufficiency, osteitis, arthritis, septic tendonitis and elephantiasis were found in 25%." (PMID: 18069381)

Finding 7 — Streptococcal erysipelas is distinct from Erysipelothrix disease

Erysipeloid (Baker-Rosenbach disease) is an occupational human skin infection caused by traumatic penetration of Erysipelothrix rhusiopathiae, presenting as a violaceous, well-demarcated erythematous edema usually on the hand/fingers, often self-limited and penicillin-responsive; it can rarely cause endocarditis (aortic valve predilection) (PMID: 19663854). In animals, E. rhusiopathiae causes swine erysipelas, with domestic pigs the principal host; 30–50% of healthy/convalescent pigs carry the organism in tonsils/lymphoid tissue, and wild boar are a potential reservoir (PMID: 42687202). It is a zoonosis affecting farmers, butchers, fishers, and veterinarians (PMID: 20171435).

"Erysipeloid is an occupational infection of the skin caused by traumatic penetration of Erysipelothrix rhusiopathiae. The disease is characterized clinically by an erythematous oedema, with well-defined and raised borders, usually localized to the back of one hand and/or fingers." (PMID: 19663854)

Finding 8 — Cochrane meta-analysis supports antibiotic prophylaxis

A 2017 Cochrane systematic review (6 RCTs, 573 evaluable participants, mean age 50–70) concluded that antibiotic prophylaxis (mainly penicillin/erythromycin) reduces recurrence risk while on treatment, with the protective effect diminishing after prophylaxis is stopped — consistent with PATCH I/II (PMID: 28631307).

"We included six trials, with a total of 573 evaluable participants, who were aged on average between 50 and 70." (PMID: 28631307)

Section-by-Section Report

1. Disease Information

Overview. Erysipelas is an acute, non-necrotizing bacterial infection of the upper dermis and superficial dermal lymphatics, classically presenting as a fiery-red, raised, well-demarcated, indurated plaque with an advancing border, warmth, tenderness, and abrupt systemic symptoms (high fever, chills). The sharp elevation and clear demarcation distinguish it from cellulitis, which involves deeper dermis and subcutaneous fat with less distinct borders. It is a clinical diagnosis made at the disease level (case series, cohorts), not from molecular/EHR variant data.

Key identifiers: - MONDO: MONDO:0001266 - ICD-10: A46 (Erysipelas); ICD-11: 1B70.0 - MeSH: Erysipelas (D004886) - SNOMED CT: 33438006 (Erysipelas) - OMIM / Orphanet: Not applicable — erysipelas is an acquired infectious disease with no Mendelian OMIM entry and is not a rare disease with an Orphanet number.

Synonyms / alternative names: St. Anthony's fire (historical), "ignis sacer," "the rose" (regional). Note that "erysipelas" in a veterinary/occupational context refers to Erysipelothrix disease (see Section 14), which must not be conflated with this streptococcal entity.

Source type: Aggregated disease-level evidence (cohorts, case-control studies, RCTs, systematic reviews); no patient-level EHR dataset was supplied for this investigation.

2. Etiology

Causal factors. Erysipelas is an infectious disease caused predominantly by β-hemolytic streptococci — S. pyogenes (GAS) and groups C/G (S. dysgalactiae); S. aureus is a less common contributor and often a colonizer (Finding 1). There is no genetic causal factor and no Mendelian inheritance.

Risk factors (environmental / host):

Genetic risk factors: None established. The Tunisian case-control study found no association with diabetes, alcoholism, or smoking after multivariate adjustment (PMID: 16484815), underlining the environmental/host-mechanical rather than genetic basis.

Protective factors: Treatment of the portal of entry (antifungal therapy for tinea pedis), edema/lymphedema control (compression, elevation), weight reduction, and — for recurrence — antibiotic prophylaxis (Findings 3, 8). No genetic protective alleles are described.

Gene–environment interactions: Not applicable in the classical sense; the disease is driven by pathogen–host barrier–lymphatic interactions rather than genotype-by-environment effects.

3. Phenotypes

Characteristics: Adult/elderly onset; acute onset (hours to 1–2 days); severity mild-to-severe (bullous, hemorrhagic, or abscess-forming variants); course episodic/recurrent. Quality-of-life impact: recurrent episodes and resulting chronic lymphedema/elephantiasis impose substantial disability, repeated hospitalization, and reduced mobility. Disease-specific QoL instruments were not identified in the reviewed literature.

4. Genetic / Molecular Information

Not applicable. Erysipelas has no causal genes, no pathogenic germline/somatic variants, no modifier genes, no disease-associated epigenetic signature, and no chromosomal abnormalities. It is an acquired infectious disease. (The molecular determinants of virulence reside in the bacterial genome — e.g., streptolysin O/S, M protein, streptokinase, hyaluronidase, C5a peptidase — PMID: 20607346; PMID: 20385762 — not the human host.)

5. Environmental Information

• Environmental / occupational: breaks in skin from trauma, animal bites/stings (insect bites are a recognized portal → erysipelas PMID: 16679881), and use of depigmenting agents (in some populations PMID: 21695874).
• Lifestyle: obesity is a strong, reproducible factor (Findings 2, 5). Smoking/alcohol were not independently associated (PMID: 16484815).
• Infectious agents (NCBITaxon): Streptococcus pyogenes (NCBITaxon:1314); S. dysgalactiae subsp. equisimilis (groups C/G, NCBITaxon:119602); occasionally Staphylococcus aureus (NCBITaxon:1280). Interdigital dermatophytes (Trichophyton spp.) act as facilitators by breaching the barrier.

6. Mechanism / Pathophysiology

Ordered causal chain:

1. Predisposing lymphatic impairment (pre-existing subclinical lymphedema, venous insufficiency, obesity) reduces local immune clearance in the dermis — demonstrated by 82% subclinical lymphedema in the unaffected leg (PMID: 40542699).
2. A breach in the cutaneous barrier (toe-web tinea, wound, dermatosis) provides a portal of entry → leads to streptococcal inoculation of the dermis (PMID: 16484815; PMID: 15822466).
3. β-hemolytic streptococci proliferate in the superficial dermis and spread along dermal lymphatics → results in the characteristic sharply demarcated, raised, advancing plaque (PMID: 26424182; PMID: 26734653).
4. Streptococcal virulence factors (streptolysin O/S, M protein, streptokinase, hyaluronidase, C5a peptidase) promote tissue spread and impair neutrophil recruitment → drives local injury and dissemination (inferred for human erysipelas from GAS biology and animal models: PMID: 20607346; PMID: 28947648; PMID: 11801184).
5. The innate immune / inflammatory response (neutrophil influx, cytokine release) produces erythema, warmth, edema, and systemic fever/chills and leukocytosis/↑CRP → causes the clinical syndrome (PMID: 41562377; PMID: 19694769).
6. Inflammatory injury to lymphatic vessels further impairs lymphatic drainage → worsens edema. [BRANCH → vicious cycle] This cumulative lymphatic damage increases susceptibility to the next episode, and repeated episodes drive chronic lymphedema → elephantiasis nostras verrucosa (subclinical lymphedema rises to 100% after ≥3 episodes: PMID: 40542699; complications incl. elephantiasis in 25%: PMID: 18069381).
7. [BRANCH → systemic] In a minority, bacteremia (blood cultures positive in ~6.9% overall) leads to invasive complications — abscess, necrotizing fasciitis, rarely myocarditis (PMID: 23498835) — associated with poor outcome (PMID: 30685804).

Lymphatic impairment ─┐
                      ├─► Barrier breach ─► Strep dermal invasion ─► Lymphatic spread
Skin breach ──────────┘                                                    │
                                                                           ▼
     ┌──────────────────  Inflammation (fever, chills, erythema)  ◄────────┤
     │                                                                     ▼
     │                                            Lymphatic vessel injury
     │                                                     │
     └──────────  VICIOUS CYCLE  ◄── worsening edema ◄─────┘
                        │
                        └─► chronic lymphedema ─► elephantiasis (~25%)

• Molecular pathways / cellular processes: innate inflammatory signaling (NF-κB–driven cytokine production), neutrophil chemotaxis and phagocytosis. GO suggestions: GO:0006954 (inflammatory response), GO:0006935 (chemotaxis), GO:0050900 (leukocyte migration), GO:0001945 (lymph vessel development, relevant to damage/repair).
• Immune involvement: acute innate response; no autoimmunity or immunodeficiency required, though HIV can predispose to severe disease/necrotizing fasciitis (PMID: 21695874).
• Cell types (CL): neutrophil (CL:0000775), keratinocyte (CL:0000312), dermal lymphatic endothelial cell (CL:0002138), macrophage (CL:0000235).

7. Anatomical Structures Affected

• Primary organ: skin (UBERON:0002097), specifically the superficial dermis (UBERON:0002067) and dermal lymphatic vessels (UBERON:0001473 lymphatic vessel).
• Body systems: integumentary and lymphatic/lymphoid system (UBERON:0002465 lymphoid system).
• Localization: lower limb / leg (UBERON:0000978 leg) in ~90% of cases (PMID: 15822466); face (UBERON:0000033 head) is the classic second site (Milian's ear sign, PMID: 32241881).
• Lateralization: typically unilateral; bilateral leg erysipelas is rare and should prompt reconsideration of the diagnosis (pseudocellulitis/stasis dermatitis, PMID: 36800152).
• Tissue/cell level: epithelial (epidermis/keratinocytes) and lymphatic endothelium; secondary organ involvement — abscess, osteitis, arthritis, septic tendonitis, rarely myocarditis (Finding 6; PMID: 23498835).

8. Temporal Development

• Onset: adult/elderly predominance (mean age 44–63 y across series); acute onset over hours, often with prodromal chills/fever preceding the rash (PMID: 41562377).
• Progression: rapid local spread over 1–3 days; self-limited with treatment (≈98% respond to penicillin within 2 days, PMID: 41562377), but strongly recurrent/episodic (recurrence 26–67% across cohorts; PMID: 15822466, PMID: 18069381).
• Patterns: treatment-induced remission is the norm; the critical intervention window is early narrow-spectrum antibiotics plus portal-of-entry and edema management to interrupt the vicious cycle. Seasonal (summer) clustering is reported (PMID: 18069381; PMID: 20147345).

9. Inheritance and Population

• Epidemiology: population-based incidence of severe lower-leg cellulitis reached 204.8/100,000 (2013), rising 4.7%/year (PMID: 29427797).
• Inheritance: none — not a genetic disease (no AD/AR/X-linked/mitochondrial pattern; no penetrance/expressivity/anticipation/founder/consanguinity/carrier-frequency parameters apply).
• Demographics: adult/elderly; female predominance in most hospital series (51–65% women); leg-predominant (~90%); comorbidities hypertension (~52%), diabetes (~42%), venous insufficiency (~36%), obesity (~12%), lymphedema (~4%) (PMID: 20147345; PMID: 15822466; PMID: 18069381).
• Geographic: cosmopolitan; toe-web intertrigo as portal of entry is prominent in warm-climate series (Tunisia, Togo).

10. Diagnostics

• Clinical diagnosis based on the characteristic sharply demarcated, raised, fiery-red plaque with acute fever/chills; constitutional symptoms preceding erythema favor erysipelas over cellulitis (PMID: 41562377).
• Laboratory: leukocytosis, elevated CRP (LOINC 1988-5), often higher in recurrent cases (PMID: 19694769). Blood cultures positive in only ~6.9% and generally low-yield (PMID: 30685804); serology (anti-streptolysin O, anti-DNase B) increases etiologic confirmation (PMID: 26734653).
• Imaging: ultrasound/MRI to exclude abscess or necrotizing fasciitis in atypical/severe presentations (PMID: 28865532).
• Differential diagnosis (critical): stasis dermatitis and other "pseudocellulitis" are frequently misdiagnosed as cellulitis/erysipelas — bilateral presentation, chronicity, and lack of fever favor pseudocellulitis; misdiagnosis drives ~$195–515M/yr in avoidable US spending and unnecessary antibiotics (PMID: 27806170; PMID: 36800152). Also exclude DVT, contact dermatitis, and necrotizing fasciitis.
• Genetic/omics testing: not applicable.

11. Outcome / Prognosis

• Favorable with prompt therapy: good outcome in 87.8% (PMID: 15822466); poor outcome in ~8.5%, reduced by guideline adherence (PMID: 30685804).
• Complications (~25%): abscess, lymphangitis, osteitis, arthritis, septic tendonitis, chronic venous insufficiency, and elephantiasis nostras verrucosa; rare systemic sequelae include myocarditis and necrotizing fasciitis (PMID: 18069381; PMID: 23498835; PMID: 21695874).
• Prognostic factors for poor outcome: bacteremia (AOR 5.21), peripheral arterial disease (AOR 4.80) (PMID: 30685804); obesity, diabetes, lymphedema for recurrence (Finding 5).
• Mortality is low for uncomplicated disease; deaths cluster in necrotizing fasciitis and immunocompromised patients (PMID: 21695874).

12. Treatment

• First-line pharmacotherapy: penicillin (penicillin G IV/IM, or oral penicillin V / amoxicillin) — narrow-spectrum, rapidly effective (Finding 4). NCIT: C692 (Penicillin), C61785 (Penicillin V). Duration typically 10 days (PMID: 15822466).
• Penicillin-allergic: macrolides (erythromycin/roxithromycin), clindamycin, or pristinamycin; a network meta-analysis found no significant cure-rate differences among first/second-line agents for cellulitis, with pristinamycin showing the highest cure rates for erysipelas (at some cost in rash) (PMID: 39240378).
• Adjunctive/emerging: omadacycline and iclaprim have activity in skin/soft-tissue infection including erysipelas (90% clinical success at end of treatment for omadacycline) (PMID: 42413095; PMID: 35928265).
• Supportive: limb elevation, edema/compression management, analgesia, and treatment of the portal of entry (topical antifungals for tinea pedis).
• Recurrence prophylaxis: low-dose penicillin V 250 mg BID (Findings 3, 8). NCIT: C15329 (Antibiotic Therapy).
• Pharmacogenomics: not applicable.

13. Prevention

• Primary: foot hygiene, prompt treatment of tinea pedis and interdigital intertrigo, wound care, weight management, and edema/venous-insufficiency control (compression) — targeting the highest-attributable, modifiable risk factors (PMID: 11319357; PMID: 16484815; PMID: 29427797).
• Secondary/tertiary: interrupting the erysipelas–lymphedema cycle through lymphedema therapy and, after ≥2 episodes, antibiotic prophylaxis with effect confirmed by RCTs and Cochrane review (Findings 3, 8). Protection wanes once prophylaxis stops, so long-term strategy must combine antibiotics with durable risk-factor modification.
• Immunization: no licensed vaccine; GAS vaccine development is ongoing but not erysipelas-specific.

14. Other Species / Natural Disease

Important distinction (Finding 7): Streptococcal erysipelas (this entry) is a human disease. The name "erysipelas" is also applied to Erysipelothrix rhusiopathiae disease: - Swine erysipelas — a veterinary disease of domestic pigs (Sus scrofa domesticus, NCBITaxon:9825); 30–50% of healthy/convalescent pigs are tonsillar carriers; wild boar (Sus scrofa) are a reservoir (45.5% tonsil culture-positive) (PMID: 42687202). - Human erysipeloid (Baker-Rosenbach disease) — a zoonotic occupational skin infection of farmers, butchers, fishers, and veterinarians, with rare systemic forms (endocarditis with aortic-valve predilection; paravertebral abscess/spondylitis) (PMID: 19663854; PMID: 20171435; PMID: 30542523; PMID: 22526696).

For streptococcal erysipelas itself, there is no significant naturally occurring companion-animal counterpart; GAS/GCS/GGS are human-adapted (GCS/GGS also colonize animals, but streptococcal erysipelas as a clinical entity is essentially human).

15. Model Organisms

Human streptococcal erysipelas is not modeled as a discrete named disease, but murine skin-infection models of S. pyogenes recapitulate key mechanistic steps: dermonecrotic/subcutaneous mouse models demonstrate the roles of streptolysin S and platelet-activating-factor acetylhydrolase Sse in inhibiting neutrophil recruitment and enabling systemic spread (PMID: 28947648; PMID: 11801184; PMID: 20385762). These are pathogen-focused models (studying bacterial virulence and innate immune evasion) rather than models of the host lymphedema cycle. Resource: MGI for mouse strains; no dedicated erysipelas model database exists. Limitation: mouse dermonecrosis models capture bacterial invasion/immune evasion but not the chronic lymphatic-damage/recurrence dynamics central to human erysipelas.

Mechanistic Model / Interpretation

Erysipelas is best understood as a two-hit, self-amplifying disease. The first hit is a susceptible host terrain — impaired lymphatic drainage (often subclinical), venous insufficiency, and obesity — that locally weakens immune surveillance. The second hit is a portal of entry (usually toe-web tinea) admitting β-hemolytic streptococci to the dermis. The organism's virulence arsenal drives rapid lymphatic spread and a brisk innate inflammatory response producing the pathognomonic plaque and systemic toxicity. Critically, that same inflammation injures lymphatics, so each episode leaves the host more vulnerable — the empirical signature being subclinical lymphedema in 74% of single-episode patients rising to 100% after ≥3 episodes. This explains why erysipelas is simultaneously highly treatable (near-universal rapid penicillin response) and highly recurrent, and why durable prevention requires attacking both hits (antifungal/portal care + edema management) alongside antibiotic prophylaxis whose benefit is real but reverses on discontinuation.

Evidence Base

Consistency: All etiologic sources converge on β-hemolytic streptococcal predominance; all risk-factor studies converge on barrier breach + edema/lymphedema + obesity; both RCTs and the Cochrane review agree on prophylaxis benefit with post-treatment waning. No reviewed study contradicted the core model.

Limitations and Knowledge Gaps

1. Etiologic uncertainty at the bedside: blood/wound cultures are low-yield (bacteremia ~6.9%); much etiologic attribution is serologic or presumptive, and S. aureus isolates may be colonizers rather than pathogens.
2. Erysipelas vs cellulitis overlap: many studies pool the two entities; findings are partly extrapolated across the boundary.
3. No molecular/host-genetic layer: because erysipelas is non-genetic, entire template sections (causal genes, variants, inheritance, pharmacogenomics) are not applicable — a structural mismatch with a genetics-oriented template, not a gap in the literature.
4. Prophylaxis durability: benefit reverses off-treatment; optimal duration and the role of combined risk-factor modification are not fully defined.
5. QoL data specific to erysipelas are sparse; no validated disease-specific instrument was identified.
6. Model systems capture bacterial virulence but not the chronic lymphedema/recurrence cycle.

Proposed Follow-up Experiments / Actions

1. Prospective interventional trial combining tinea pedis eradication + compression lymphedema therapy vs standard care to quantify reduction in first and recurrent episodes (targets the highest-attributable, modifiable factors).
2. Biomarker study correlating baseline lymphoscintigraphy and CRP kinetics with recurrence, to risk-stratify candidates for prophylaxis.
3. Comparative-effectiveness / duration study of penicillin prophylaxis (e.g., 12 vs 24 months, continuous vs intermittent) with off-treatment follow-up to address waning.
4. Curation action: ensure the knowledge base cleanly separates MONDO:0001266 (streptococcal erysipelas) from Erysipelothrix erysipeloid/swine erysipelas to prevent conflation.
5. Diagnostic stewardship: deploy/validate clinical decision tools to reduce pseudocellulitis misdiagnosis and unnecessary antibiotic use.

Report compiled from 5 discovery iterations, 8 confirmed findings, and 44 reviewed papers. Evidence is predominantly human clinical (cohort, case-control, RCT, systematic review), supplemented by murine pathogen-virulence models and veterinary/zoonotic sources for the nosological distinction.